Basic Drug Information
\nGeneric Name\u200c: eltrombopag olamine
\nBrand Name\u200c: REVOLADE
\nDosage Form & Strength\u200c: film coated tablet; 12.5mg\/25mg\/50mg\/75mg (counted as eltrombopag)
\nMarketing Authorizer\u200c: Novartis
\nMechanism of Action: oral thrombopoietin receptor (TPO-R) agonist
\nIndications and Usage<\/p>\n
Revolade is indicated for:<\/p>\n
Treatment of \u200cchronic immune (idiopathic) thrombocytopenia (ITP)\u200c in adult and pediatric patients 6 years of age and older who have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy, to increase platelet counts and reduce or prevent bleeding.
\nIt is only indicated for patients with ITP where the degree of thrombocytopenia and clinical situation increases the risk of bleeding. It is not intended to normalize platelet counts.
\nDosage and Administration
\nRecommended Initial Dosage for Adults\u200c: 50 mg once orally; for East Asian patients or patients with moderate to severe hepatic impairment, initial dosage is 25 mg once daily.
\nAdministration Requirements\u200c: Take on an empty stomach, at least 2 hours before or 4 hours after food\/medications\/supplements containing polyvalent cations (aluminum, calcium, iron, magnesium, selenium, zinc). Do not split, chew, crush tablets or mix with food\/liquid.
\nDosage Adjustment\u200c: Adjust dose based on platelet count response, to maintain platelet count \u2265 50\u00d710\u2079\/L. Maximum daily dose is 75 mg. Discontinue therapy if no hematologic response after 16 weeks of treatment.
\nDosage Forms and Strengths<\/p>\n
Tablet specifications (eltrombopag equivalent): 12.5mg (white, imprinted GS MZ1 12.5), 25mg (white, imprinted GS NX3 25), 50mg (brown, imprinted GS UFU 50), 75mg (pink, imprinted GS FSS 75), all supplied in packs of 28 tablets.<\/p>\n
Contraindications<\/p>\n
Hypersensitivity to eltrombopag olamine or any excipients of the product is contraindicated.<\/p>\n
Warnings and Precautions
\nHepatotoxicity\u200c: May cause severe life-threatening hepatotoxicity, monitor liver function regularly. Discontinue treatment if significant liver test abnormalities occur.
\nThrombosis\/Thromboembolism\u200c: Increased risk when platelet count is above normal range, use with caution in patients with existing thrombotic risk factors.
\nBleeding after Discontinuation\u200c: Platelet count usually returns to baseline within 2 weeks after stopping treatment, which increases bleeding risk.
\nBone Marrow Reticulin Fibrosis\u200c: May increase the risk of reticulin fiber formation and progression in bone marrow.
\nOverdosage<\/p>\n
In case of overdose, orally administer a preparation containing metal cations (such as calcium, aluminum, or magnesium preparations) to chelate eltrombopag and limit absorption. Closely monitor platelet counts. Hemodialysis is not expected to effectively enhance elimination because Revolade is not significantly renally excreted and is highly bound to plasma proteins.<\/p>\n","protected":false},"excerpt":{"rendered":"
Generic Name\u200c: eltrombopag olamine
\nBrand Name\u200c: REVOLADE
\nDosage Form & Strength\u200c: film coated tablet; 12.5mg\/25mg\/50mg\/75mg (counted as eltrombopag)
\nMarketing Authorizer\u200c: Novartis
\nMechanism of Action: oral thrombopoietin receptor (TPO-R) agonist<\/p>\n","protected":false},"featured_media":2590,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[80],"product_cat":[27],"product_tag":[],"class_list":["post-2361","product","type-product","status-publish","has-post-thumbnail","product_brand-novartis","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n